Human papillomavirus type 18 L1 capsid protein residues 2-472 antigen

DB10995ApprovedWithdrawnVaccines

Human papillomavirus type 18 L1 capsid protein residues 2-472 antigen is one antigen component of a recombinant bivalent HPV vaccine. A component of a vaccine that protects against human papillomavirus (HPV), a virus that can cause cervical cancer.

First approval: United States, 2009

Resolves to

Compound

UNIIM7H9CF9G0Z

Clinical / RWD

RxNorm1301887

What you can answer from here — as of April 02, 2025

1ContraindicationEach with its own population and attribute set

11Marketed productsAcross 3 countries and 2 labellers

Which companies are running trials of Human papillomavirus type 18 L1 capsid protein residues 2-472 antigen, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account